Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

_blank" href= "http://www.yourcanceryourchoice.com/">http://www.yourcanceryourchoice.com. Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

Alimta(R) and Gemzar(R) are registered trademarks of Eli Lilly and Company.

Tarceva(R) is a registered trademark of Genentech.

Taxotere(R) is a registered trademark of Sanofi-Aventis.

NOTE: Other than statements of historical fact, the statements made in this press release about plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to obtain future financing and fund the product development of our pipeline; the possibility that the FDA refuses to approve our NDA; because our Phase 3 clinical trial known as the SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial failed to meet its primary endpoint, the FDA may require additional data, analysis or studies before the NDA is approved by the FDA; the outcome of any discussions with the FDA; the initiation, t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/10/2014)...  The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... 10, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year ended June 30, 2014 results on Thursday, July ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Sept. 7 According to Millennium Research Group (MRG), ... in Japan,s Ministry of Health Labour and Welfare (MHLW) ... catheters, will lead to double-digit growth in this segment ... market revenues. Unlike in the US ...
... Reportlinker.com announces that a new market research ... Drug Delivery in Central Nervous System Diseases ... http://www.reportlinker.com/p0203542/Drug-Delivery-in-Central-Nervous-System-Diseases---technologiesmarkets-and-companies.html SummaryThe delivery ... a challenge in the treatment of neurological disorders. ...
Cached Medicine Technology:Will MHLW Changes in Reimbursement Drive Japanese Physicians to Increase Usage of Chronic Dialysis Catheters? 2Will MHLW Changes in Reimbursement Drive Japanese Physicians to Increase Usage of Chronic Dialysis Catheters? 3Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 2Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 3Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 4Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 5Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 6Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 7Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 8Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 9Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 10Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 11Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 12Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 13Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 14Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 15Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 16Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 17
(Date:7/12/2014)... July 12, 2014 Tylenol lawsuits ... to move forward in the federal multidistrict litigation ... Pennsylvania, Bernstein Liebhard LLP reports. According to a ... Lawrence F. Stengel has ordered the deposition of ... Stengel found that the witness’s testimony concerning the ...
(Date:7/12/2014)... "The second toes cross over the big ... wear shoes," said an inventor from East Hartford, Conn. This ... from happening. , He then created a prototype of the ... second and big toes from overlapping. This avoids discomfort and ... and easy to use, it's ideal for people with foot ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As DePuy ... forward in U.S. courts, Bernstein Liebhard LLP notes the ... ion levels to the failure of metal-on-metal hip replacements. ... of The Journal of Bone & Joint Surgery, looked ... Articular Surface Replacement prostheses at least twelve months earlier. ...
(Date:7/12/2014)... July 12, 2014 “Critical Care ... New and Late-Stage Four-Factor PCCs and Recombinant Products ... the critical care market in the US, UK, ... report provides an estimation of market size for ... covers critical care indications that are being treated ...
(Date:7/12/2014)... Emirates (PRWEB) July 12, 2014 Dubai ... Angeles basketball legend is heading to the UAE. ... six-time champion will be in the UAE from 28-31 ... Weekend in support of diabetes awareness. The event is ... entertainment marketing and event management company based in Dubai. ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3
... Just another AccessorySCARBOROUGH, N.Y., March 4 No hair? ... ( BaldGirlsDoLunch.org ) brings women with alopecia areata ... heads will turn. That delights founder Thea Chassin ... hair normally. It,s time for everyone to understand it ...
... logged on to www.WorldMedAssist.com to help him find the surgeon in ... of ICU with his mitral valve replacement overseas completed. He,s now home ... ... -- When Henry Konczak first learned that his chronic fatigue was due to ...
... its advanced mobile health screening services to the ... and techniques in the industry, HealthYes! screens its clients for ... peripheral artery disease and osteoporosis. , ... ...
... detect and measure pneumothoraces in trauma patients helps physicians ... room settings, according to a study performed at Massachusetts ... , "With the rapid development of ... trauma patients replaced traditional x-ray radiography in emergency care ...
... the Journal of Clinical Endocrinology & Metabolism , ... of clinical medicine and director of the Diabetes Clinical ... with age. An estimated 37 million Americans over the ... population. Another 20 to 30 percent of seniors, an ...
... Healthcare Sustainability for America,s Hospitals and Medical ... Healthcare Waste and Emergency Preparedness Coalition (CleanMedWaste.org) ... provide education about two major problems facing ... operational sustainability during a crisis and the ...
Cached Medicine News:Health News:Seattle's First Bald Girls Do Lunch(R) 2Health News:Seattle's First Bald Girls Do Lunch(R) 3Health News:Ohio Patient Thanks India and WorldMed Assist For Heart Surgery Overseas; His Indian Surgeon Thanks U.S. for Superb Training 2Health News:Ohio Patient Thanks India and WorldMed Assist For Heart Surgery Overseas; His Indian Surgeon Thanks U.S. for Superb Training 3Health News:HealthYes! Now Offering its Preventive Health Screening Services in Houston 2Health News:HealthYes! Now Offering its Preventive Health Screening Services in Houston 3Health News:Computer-aided system effectively detects and measures pneumothoraces in chest trauma patients 2Health News:'Pre-diabetics' face heightened risk of heart disease 2Health News:The Healthcare Waste and Emergency Preparedness Coalition Announces Its Official Formation 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: